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Patients demographic, laboratory, echocardiographic data
All population
3913
Age (years) 61.1 ± 12.5
Height (cm) 170 ± 8
Gender (males) 3268 (84%)
BMI (Kg/m2) 26.8 ± 4.4
NYHA I 574(14.7%)
NYHA II 2197(56.2%)
NYHA III 1091(27.9%)
NYHA IV 49 (1.2%)
Idiopathic etiology 1659 (42.5%)
Ischaemic etiology 1884 (48.2%)
Valvular etiology 130 (3.3%)
Other etiology 234 (6.0%)
Hemoglobin (g/dL) 13.6 ± 1.6
K+ (mmol/L) 4.3(4.0;4.6)
Creatinine (mg/dL) 1.10 (0.9;1.31)
Na+ (mmol/L) 139.3 ± 3.3
MDRD (mL/min/1.73 m2) 71.7 ± 23.3
LVeSV (mL) 116 (83;157)
LVeDV (mL) 174 (130;220)
LVEF (%) 31.8 ± 9.4
Atrial ﬁbrillation 617(15.8%)
Continuous data are reported as Mean ± SD or Median (7
BMI = Body Mass Index, NYHA= New York Heart Assoc
Disease, LVeSV= left ventricle end-systolic volume, LVeDV
LVeDV= Left Ventricular End-Diastolic Volume.(17%) patients had very low (b11 g/dL), low (11–12 for females, 11–13 for males), normal (12–15 for females,
13–15 for males) and high (N15) Hb, respectively.
Results:Median follow-up was 1363 days (606–1883). CPETs were always performed safely. Hb was related to
prognosis (Hazard ratio (HR) = 0.864). No prognostic difference was observed between normal and high Hb
groups. Peak oxygen consumption (VO2), ventilatory efﬁciency (VE/VCO2 slope), plasma sodium concentration,
ejection fraction (LVEF), kidney function and Hb were independently related to prognosis in the entire popula-
tion. Considering Hb groups separately, peakVO2 (very low Hb HR = 0.549, low Hb HR = 0.613, normal Hb
HR = 0.618, high Hb HR = 0.542) and LVEF (very low Hb HR = 0.49, low Hb HR = 0.692, normal Hb HR =
0.697, high Hb HR = 0.694) maintained their prognostic roles. High VE/VCO2 slope was associated with poor
prognosis only in patients with low and normal Hb.
Conclusions: Anemic HF patients have a worse prognosis, but CPET can be safely performed. PeakVO2 and LVEF,
but not VE/VCO2 slope, maintain their prognostic power also in HF patients with Hb b 11 g/dL, suggesting
CPET use and a multiparametric approach in HF patients with low Hb. However, the prognostic effect of an
anemia-oriented follow-up is unknown.
© 2016 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.Keywords:
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Heart failure
Prognosis1. Introduction
Anemia is frequent in heart failure (HF), although a considerable
variability of its prevalence has been reported [1]. As an average, anemia
is reported in 22% of HF patients with Left Ventricular Ejection Fraction
(LVEF) N50%, in 20% of HF patients with LVEF from 40% to 49% and in
14% of HF patients with LVEF b40% [2–7]. The presence of anemia, as
an independent risk factor, is associated with a higher all-cause mortal-
ity or hospitalization rate [2–7], and it is among themost important risk
scores for HF [8,9].
However, limited data are available about the predictive power of
established HF prognostic parameters in anemic HF patients. In fact,
anemia is a common exclusion criterion in HF trials. Notably, exercise-
derived HF prognostic parameters, such as peak oxygen consumption
(peakVO2) and ventilatory efﬁciency (VE/VCO2), are rarely available in
anemic HF patients due to the controversy about the safety of anemic
patients performing exercise [10]. Moreover, the meaning of peakVO2
in HF patients with anemia is questionable, as hemoglobin (Hb) is a
component of VO2.
In order to improve the risk stratiﬁcation and the clinical man-
agement of the growing population of HF patients with anemia, we.
Very low Hb Low Hb
248 (6%) 857 (22%)
65.2 ± 12.4 63.0 ± 12
168 ± 8 169 ± 8
193 (78%) 755 (88%)
26 ± 4.3 26.2 ± 4.1
17 (6.8%) 86 (10.0%
122 (49.2%) 464 (54.2
103 (41.5%) 294 (34.3
6 (2.4%) 12 (1.4%)
81 (32.6%) 299 (35.0
133 (53.6%) 476 (55.7
19 (7.7%) 35 (4.1%)
15 (6.0%) 44 (5.1%)
10.3 ± 0.7 12.1 ± 0.
4.2 (3.9;4.6) 4.3 (4.0;4
1.29 (1.03;1.73) 1.16 (0.94
138.6 ± 3.5 139.1 ± 3
59.0 ± 24.9 67.6 ± 25
116 (82;152) 119 (85;1
168 (128;211) 176 (132;
31.9 ± 9.8 31.4 ± 9.4
46 (18.5%) 132 (15.4
5–25 interquartile). Categorical varia
iation, Na+= plasma sodium conce
= left ventricle end-diastolic volumaimed at assessing the prognostic power of several parameters by
analyzing the multicenter Italian database (MECKI score research
group) [8]. This is built with several established HF prognostic pa-
rameters such as clinical, laboratory, echocardiographic and exercise
measurements. In particular, we assessed the role of HF prognostic
parameters in patients with different Hb values using, as a study
endpoint, the composite of cardiovascular death and urgent heart
transplant (HT).
2. Methods
2.1. Study population
The study cohort consisted of 3913 consecutive patients with systol-
ic HF, recruited and prospectively followed in 19 Italian HF Centers
(MECKI score research group) [8]. Inclusion criteria were: HF symptoms
(NYHA functional class I-IV, stage C of ACC/AHA classiﬁcation), previous
documentation of left ventricular systolic dysfunction (LVEF b40%), sta-
ble clinical conditions with unchanged medications for at least three
months, no major cardiovascular treatment or intervention scheduled.
Exclusion criteria were: history of pulmonary embolism, moderate toNormal Hb High Hb
2160 (55%) 648 (17%) P (Trend) p(Class)
.9 60.8 ± 12.0 57.9 ± 12.5 b0.001 b0.001
170 ± 8 171 ± 7 b0.001 b0.001
1689 (78%) 631 (97%) b0.0001 b0.0001
26.9 ± 4.4 27.6 ± 4.6 b0.001 b0.001
) 331 (15.3%) 140 (21.6%) b0.0001 b0.0001
%) 1247 (57.7%) 364 (56.3%)
%) 556 (25.7%) 138 (21.3%)
26 (1.2%) 5 (0.8%)
%) 964 (44.7%) 315 (48.7%) b0.0001 b0.0001
%) 986 (45.7%) 289 (44.7%)
65 (3.0%) 11 (1.7%)
143 (6.6%) 32 (4.9%)
5 13.8 ± 0.7 15.8 ± 0.6 b0.001 b0.001
.6) 4.27 (4.0;4.6) 4.3 (4.0;4.6) 0.21 0.02
;1.5) 1.05 (0.9;1.27) 1.08 (0.93;1.22) b0.001 b0.001
.3 139.4 ± 3.2 139.7 ± 3.2 b0.001 b0.001
.4 73.2 ± 21.8 77.1 ± 22.0 b0.001 b0.001
60) 115 (82;156) 118 (85;163) 0.11 0.06
222) 172 (129;219) 180 (136;225) 0.05 0.02
32 ± 9.4 31.8 ± 9.1 0.53 0.57
%) 326 (15.1%) 113 (17.4%) 1 0.31
ble are reported as frequency (%).
ntration, K += plasma potassium concentration, MDRD =Modiﬁcation of Diet in Renal
e, LVEF= Left Ventricular Ejection Fraction, LVeSV=Left Ventricular End-Systolic Volume,
Table 2
Therapy (drugs and devices) at study run-in.
All population Very low Hb Low Hb Normal Hb High Hb
3913 248 (6%) 857 (22%) 2160 (55%) 648 (17%) p(Trend) p(Class)
ACE-inhibitors 2994 (76.6%) 174 (70.2%) 640 (74.8%) 1660 (77.1%) 520 (80.2%) b0.01 b0.01
ARB-blockers 695 (17.8%) 51 (20.6%) 154 (18.0%) 397 (18.4%) 93 (14.4%) 0.04 0.07
Beta-blockers 3312 (84.6%) 202 (81.5%) 716 (83.5%) 1850 (85.6%) 544 (84.0%) 0.24 0.20
Diuretics 3188 (81.5%) 215 (86.7%) 736 (85.9%) 1758 (81.4%) 479 (73.9%) b0.001 b0.001
Anti-aldosteronic drugs 2111 (54.0%) 144 (58.1%) 506 (59.1%) 1147 (53.2%) 314 (48.5%) b0.001 b0.001
Anti-platlets drugs 2101 (53.8%) 139 (56.0%) 490 (57.2%) 1142 (53.0%) 330 (50.9%) 0.01 0.06
Anticoagulants 1139 (29.1%) 80 (32.3%) 276 (32.2%) 599 (27.8%) 184 (28.4%) 0.03 0.07
Digitalis 898 (23.0%) 53 (21.4%) 197 (23.1%) 480 (22.2%) 168 (25.9%) 0.20 0.24
Amiodarone 979 (25.1%) 62 (25.0%) 227 (26.5%) 542 (25.2%) 148 (22.8%) 0.21 0.44
PM 734 (18.8%) 69 (27.9%) 218 (25.6%) 354 (16.5%) 93 (14.4%) b0.001 b0.001
ICD 1157 (30.0%) 82 (33.5%) 310 (36.5%) 598 (28.1%) 167 (26.5%) b0.001 b0.001
CRT 473 (13.1%) 38 (16.4%) 140 (17.8%) 232 (11.7%) 63 (10.5%) b0.001 b0.001
ACE = angiotensin I converting enzyme, ARB = angiotensin II receptor, PM= Pace-maker, ICD = Implantable Cardioverter-Deﬁbrillator, CRT = Cardiac.
Resynchronization Therapy.
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lung disease, exercise-induced angina and signiﬁcant electrocardio-
graphic alterations or presence of any clinical comorbidity interfering
with exercise performance.
2.2. Clinical, laboratory, echocardiographic and CPET evaluations
At enrollment, patients' clinical history, treatment, physical, labora-
tory, EKG, echocardiographic and cardiopulmonary exercise test
(CPET) data were collected. Among the parameters recorded, we ana-
lyzed: a) patients' NYHA class, weight, height and treatment; b) HF eti-
ology, deﬁned as dilative ischemic and non-ischemic cardiomyopathy
(on the basis of the presence or absence of relevant stenosis at coronary
angiography, respectively) or cardiomyopathy secondary to valvular
disease and to other causes; c) Hb, plasma sodium concentration
(Na+), plasma potassium concentration (K+), and creatinine.We calcu-
lated glomerular ﬁltration rate asMDRDby using the following formula:
186.3 * (creatinine)−1154 * (Age)-0.203 * 0,75 for women [11]. Moreover,
we analyzed several EKG and CPET parameters and, at echocardiogra-
phy, left ventricle end-systolic (LVeSV) and end-diastolic volumes
(LVeDV) and LVEF (Simpson's rule) [12]. All CPETs were performed
using either an electronically braked cycle ergometer (3596 patients)
or a treadmill (317 patients); for a proper comparison, the VO2 dataTable 3
Patients CPET data.
All population Very low Hb Low Hb
3913 248 (6%) 857 (22%
Ramp protocol (Watt/min) 9.9 ± 2.3 9.5 ± 2.2 9.7 ± 2.1
Peak VO2 (% pred) 55.5 ± 16.5 47.7 ± 15.3 49.8 ± 1
Peak VO2 (mL/Kg/min) 14.3(11.6;17.4) 11.71(9.7;14.2) 13.2(10.8
Peak HR (bpm) 121 ± 25 114 ± 25 117 ± 24
Peak HR (% pred) 77 ± 15 75 ± 17 75 ± 16
Peak Load (Watt) 83 ± 33 65 ± 24 73 ± 27
Peak pulse (mL/bpm) 9.7 ± 3.5 8.2 ± 2.9 8.9 ± 2.9
Peak VT (L) 1.5 ± 0.5 1.3 ± 0.4 1.4 ± 0.4
Peak RR (bpm) 31 ± 7 32 ± 7 31 ± 7
Peak VE (L/min) 44.6(36.1;54.7) 40.2(32.8;48) 42.7(34.8
RQ 1.11 ± 0.13 1.14 ± 0.14 1.13 ± 0
VO2 at AT (mL/Kg) 10.3 ± 3.3 8.9 ± 2.8 9.6 ± 2.7
VO2 at AT (%) 68.3 ± 13.9 70.4 ± 15.6 69.4 ± 1
Load at AT (Watt) 50 ± 23 39 ± 16 44 ± 18
HR at AT (bpm) 97 ± 19 93 ± 17 94 ± 18
VO2/work slope 9.73 ± 2.13 9.42 ± 2.61 9.45 ± 2
VE/VCO2 slope 32.5 ± 7.6 35.5 ± 8.1 34.2 ± 8
Periodic breathing 682(17.5%) 63(25.4%) 171(20%)
Continuous data are reported as Mean ± SD or Median (75–25 interquartile). Categorical varia
VO2 = Oxygen consumption, HR = Heart-rate, TV = Tidal Volume, RR = Respiratory-rate, V
Carbon Dioxide Consumption, PB = Periodic Breathing.measured on treadmill were reduced by 10% [13]. In CPETs performed
on cycle ergometer, a ramp protocol was applied, while treadmill
studies were performed using a modiﬁed Bruce protocol. The exercise
protocol was set to achieve peak exercise in ~10 min [14]. CPETs were
interrupted when patients stated that they had reachedmaximal effort.
We performed breath-by-breath analysis of expiratory gases and venti-
lation. Anaerobic threshold (AT) was measured by V-slope analysis of
VO2 and VCO2, and it was conﬁrmed analyzing the ventilatory equiva-
lents and the end-tidal pressures of CO2 andO2. If no agreementwas ob-
tained or AT was not detected, AT was considered as not identiﬁed.
Exercise-induced periodic breathing was deﬁned as a cyclic ﬂuctuation
of ventilation [15]. VE/VCO2 slope was calculated as the slope of the lin-
ear relationship between VE and VCO2 from 1min after the beginning of
loaded exercise to the end of the isocapnic buffering period. Peak exer-
cise oxygen pulsewas calculated as peak VO2/peak heart rate (HR). Pre-
dicted values of HR were calculated as: peak HR pred= (220− Age), if
male, =(210− Age) if female [13].
2.3. Patient follow-up and prognosis
Patient follow-upwas carried out according to the local HF program.
Follow-up ended with the last clinical evaluation in the Center where
the patient had been enrolled or with the patient's death or urgent HT.Normal Hb High Hb
) 2160 (55%) 648 (17%) p(Trend) p(Class)
9.9 ± 2.3 10.4 ± 2.6 b0.001 b0.001
4.3 57.4 ± 16.5 59.6 ± 16.8 b0.001 b0.001
;15.6) 14.6(11.8;17.8) 15.9(13.2;19.3) b0.001 b0.001
122 ± 24 127 ± 26 b0.001 b0.001
78 ± 15 78 ± 15 b0.001 b0.001
85 ± 33 97 ± 35 b0.001 b0.001
9.9 ± 3.6 10.8 ± 3.3 b0.001 b0.001
1.5 ± 0.5 1.7 ± 0.5 b0.001 b0.001
31 ± 7 31 ± 7 0.32 0.55
;50.8) 44.9(36.2;55) 49.6(39.9;59.8) b0.001 b0.001
.12 1.11 ± 0.13 1.10 ± 0.12 b0.001 b0.001
10.5 ± 3.4 11.3 ± 3.6 b0.001 b0.001
3.3 67.9 ± 13.8 67.5 ± 14.1 0.001 0.0066
52 ± 24 57 ± 24 b0.001 b0.001
98 ± 20 100 ± 21 b0.001 b0.001
.05 9.79 ± 2.08 10.07 ± 2.14 b0.001 b0.001
.1 32.0 ± 7.3 30.8 ± 6.8 b0.001 b0.001
352(16.3%) 96(14.8%) b0.001 b0.001
ble are reported as frequency (%).
E = Ventilation, RER = Respiratory Exchange Ratio, AT = Anaerobic Threshold, VCO2 =
Table 4
Follow up, cardiovascular deaths and urgent heart transplants for the entire study population and grouped for different hemoglobin values.
All population Very low Hb Low Hb Normal Hb High Hb p-value
3913 248 (6%) 857 (22%) 2160 (55%) 648 (17%)
Median follow up (days) 1363 1250 1221 1072 946
(interquartile range) (606–1883) (678–1994) (629–1912) (575–1736) (439–1614) b0.0001
Cardiovascular deaths 541 67 149 255 70 b0.0001
(CV deaths/1000 persons/years) (37) (85) (49) (31) (27) b0.0001
Urgent HTs 105 6 22 54 23 0.52
(Urgent HTs/1000 persons/years) (7) (7) (7) (7) (9) 0.73
Cardiovascular Deaths + Urgent HTs 646 73 171 309 93 b0.0001
(Cardiovascular Deaths + Urgent HTs/1000 persons/years) (44) (92) (56) (38) (36) b0.0001
CV = cardiovascular; HT = heart transplant.
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Data management was that of the MECKI score research group, as
previously reported [8]. Data were analyzed for the entire study popula-
tion and grouping patients according to Hb value (high Hb: N15 g/dL;Fig. 1. Hazard ratio according to Hemoglobin levels. Hazard Ratio of cardiovascular death + h
normal Hb, low Hb and very low Hb (lower panel).normal Hb: 13–15 g/dL for males and 12–15 g/dL for females; low
Hb: 11–13 g/dL for males and 11–12 g/dL for females; very low Hb:
b11 g/dL [16]).
An institutional review committee approved the study, and the sub-
jects gave informed consent.eart transplant for hemoglobin (Hb) (upper panel) and for patients grouped for high Hb,
Fig. 2. Multivariable model for Hazard Ratio in the entire population. Hazard Ratio for
association between peak oxygen consumption (VO2), ventilatory efﬁciency (VE/VCO2),
Na+, left ventricle ejection fraction (LVEF), renal function (MDRD), Hb and
cardiovascular death + heart transplant through study follow-up in the entire study
population. Each variable is adjusted for the other variables of the model (VO2, VE/VCO2,
Na+, LVEF, MDRD, Hb).
60 G. Cattadori et al. / European Journal of Internal Medicine 37 (2017) 56–632.5. Statistical methods
Categorical variables were presented as frequency and percentage,
and they were compared by chi-square test. Numerical variables were
summarized as means ± SD or medians and interquartile range when
their distribution was markedly not normal. Multivariable model for
Hazard Ratio was performed when the entire population was analyzed.
Each variable is adjusted for the other variables of the model (VO2, VE/
VCO2, Na+, LVEF, MDRD, Hb). Unpaired t-test or non-parametric
Mann–Whitney test were used as appropriate for between-group com-
parison. Kaplan–Meier curves were constructed and analyzed by Odds
Ratio (OR). A p b 0.05was used to deﬁne statistical signiﬁcance. All anal-
yseswere performed using SPSS 18 software and SAS statistical package
v.9.2 (SAS Institute Inc., Cary, NC).3. Results
Table 1 presents the characteristics of the entire study population
(3913 HF patients) and differentiated according to Hb levels in very
low (248; 6%), low (857; 22%), normal (2160; 55%), and high (648;
17%) Hb. Ischemic etiology was more frequently observed in patientswith low Hb, while an opposite trend was observed in patients with
HF due to idiopathic cardiomyopathy. Treatmentwas up to date accord-
ing to guidelines (Table 2). However, ACE-inhibitors and ARB-blockers
combined were similar among the Hb classes, as beta-blockers were. A
non-signiﬁcant trend toward more anti-coagulant and anti-platelet
therapy was observed in patients with low and very low Hb level.
LVEF was similar among Hb groups. CPETs were performed safely in
all patients; speciﬁcally, no CPET-related death or cardiac arrest was re-
corded. CPET data are reported in Table 3. Peak VO2 and VE/VCO2 slope
were progressively lower and higher as Hb decreased. The very low Hb
group was characterized by the most severe patients in terms of NYHA
class, laboratory (Na+ andMDRD), CPET-derived parameters and treat-
ment strategy (more diuretics).
Median follow-up was 1363 days (interquartile range 606–1883) in
the entire population. During follow-up, 541 (37 per 1000 persons/
year) cardiovascular deaths and 100 (7 per 1000 persons/year) urgent
HTs were observed (Table 4). Follow-up, cardiovascular deaths and ur-
gent HTs in the study population grouped for different Hb values are
also reported in Table 4.
Anemia was related to prognosis, as shown by the Hazard Ratio of
study endpoint in the entire population (Fig. 1, upper panel) and in pa-
tients grouped according to Hb level (Table 4, Fig. 1, lower panel). Nota-
bly, no differences in prognosis were observed between normal Hb and
high Hb groups.
We tested for prognosis all the variables reported in Tables 1, 2 and 3
using the same statistical approach that allowed us to derive theMECKI
score [8]. In the overall population, we conﬁrmed that PeakVO2 (% of
predicted), VE/VCO2 slope, Na+, LVEF, MDRD and Hb were indepen-
dently related to prognosis (Fig. 2). Kaplan–Meier curves of the four
Hb groups and adjusted for the proven confounders, i.e. peak VO2, VE/
VCO2 slope, MDRD, LVEF and Na+, are reported in Fig. 3. Low Hb and
very low Hb curves diverged already after 1 year. At 5 years, patients
with very lowHbhad a signiﬁcant reductionof survival compared to pa-
tients with lowHb (OR 2.1), with normal Hb (OR 3.0), andwith high Hb
(OR 3.3).
The independent predictive role of PeakVO2, VE/VCO2 slope, Na+,
LVEF, and MDRD were also assessed in the four Hb-based groups
(Fig. 4). PeakVO2 and LVEF maintained their prognostic roles in all Hb
groups. The same happened, at least as a trend, for kidney function
and Na+. Differently, a high VE/VCO2 slope was associated with poor
prognosis only in patients with normal and low Hb, but not in those
with very low or high Hb.
4. Discussion
This study leads to a number of important ﬁndings. Firstly, in line
with several previous reports [2–6], we conﬁrmed that anemia inﬂu-
ences HF prognosis. Secondly, there is a direct correlation between Hb
level and prognosis below but not above Hb = 12 g/dL. Thirdly, CPET
can be performed safely in anemic HF patients. Finally, among CPET pa-
rameters, peakVO2, but not VE/VCO2 slope,maintains its prognostic role
in very low Hb HF patients.
In clinical practice, aswell as in a previous position paper report [10],
concernswere raised about performing exercise in patients with severe
anemia, suggesting that any exercise test be postponed until anemia
correction is obtained. In the present study, we showed that CPET can
be safely performed even in HF patients with very low Hb. Moreover,
in patients with severe anemia, peakVO2 maintains its strong prognos-
tic role, conﬁrming the role of CPET in proper prognosis even in this
setting of HF patients. It is of note that the prognostic role of peakVO2
is independent of anemia although anemia is a component of VO2, likely
because several other physiological mechanisms, such as cardiac
output, O2 delivery, or muscular O2 utilization, are involved in VO2
determination.
The prevalence of anemia we observed in the present population of
HF patients with low LVEF is similar to that previously reported [1–7].
Fig. 3. Population mortality according to Hemoglobin levels. Kaplan–Meier curves for cardiovascular death + heart transplant adjusted for age, gender adjusted for the proven
confounders, i.e. peak VO2, VE/VCO2 slope, MDRD, LVEF and Na+ in the entire study population stratiﬁed according to Hb values: high Hb: N15 g/dL (black line); normal Hb: 13–15 g/
dL for males and 12–15 g/dL for females (green line); low Hb: 11–13 g/dL for males and 11–12 g/dL for females (red line); very low Hb: b11 g/dL (blue line). The curves were
arbitrarily ended at 10 years.
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nostic evaluation is a composite of different parameters, including Hb,
peak VO2, LVEF and, at least as a trend, Na+ and kidney function. Ac-
cordingly, our ﬁndings are in line with the concept that the most pow-
erful prognostic capacity is obtained with a multiparametric approach
even in patients with combined anemia and HF [8].
The ﬁnding that VE/VCO2 slope is not associated with prognosis in
patients with Hb b 11 g/dL was unexpected, although the VE/VCO2
slope value in patients with low Hb was the highest observed. In-
deed, these patients have very severe HF with a poor prognosis,
and VE/VCO2 slope is a recognized strong HF prognosis predictor
[17,18]. There are several possible explanations for this ﬁnding.
However, we are intrigued by a physiological hypothesis. Indeed, a
high VE/VCO2 slope in HF is related to an increase of sympathetic ac-
tivity through a CO2-dependent stimulation of metaboreceptors and
chemoreceptors. In severe anemia, the reduction of O2 delivery due
to low arterial oxygen content may per se stimulate ventilation,
and therefore it may overwhelm the role of CO2-dependent reﬂex
hyperventilation. In patients with Hb N 15, the ones with the lowest
VE/VCO2 slope value observed, a relatively increased oxygen delivery
may counterbalance the increase of sympathetic activity on ventila-
tion, explaining why, as happens in severe anemic patients, VE/VCO2
loses its prognostic power. It is of note that the present ﬁndings ﬁt
very well with the most recent hypothesis of ventilation regulation
by O2, which is mediated by an olfactory receptor activated by lactate
[19]. This hypothesis suggests that O2 delivery to the glomus cell of
the carotid body, and not PO2, regulates ventilation. Consequently,
in the very low Hb group, an anemia-related low O2 delivery to the
carotid chemoreceptors may overwhelm the sympathetic-induced
chemoreceptor and metaboreceptor hyperactivity, so that the VE/
VCO2 slope, albeit very high, loses its prognostic power. Notably,
the same seems to be true for the high Hb group, albeit through an
opposite mechanism. It is recognized, however, that further studies
are needed to conﬁrm the present ﬁndings that cast some doubtsabout the prognostic role of VE/VCO2 slope in HF patients with very
low and high Hb values.
Finally, in line with a recent analysis performed in HF patients [2],
we showed that prognosis in systolic HF patients with N15 g/dL Hb
value is unrelated to Hb, suggesting that Hb values between 15 and 17
are not associated with an increase of cardiovascular deaths.4.1. Study limitations
This study has several limitations. Firstly, the follow-up was a long
one, on average around 4 years, but we analyzed Hb values only at
study enrollment. Moreover, patients were studied and followed up in
19 HF units, each one with its own patient follow-up program. Accord-
ingly, we do not know whether and how often Hb level was checked
and if anemia treatment was carried out and how effective the anemia
treatment strategy was. It is therefore possible that patients varied
their Hb during follow-up, either reducing it with HF worsening or in-
creasing it because of proper therapeutic interventions. It is recognized
that all these factors could have modiﬁed the impact of anemia on HF
prognosis.
Secondly, the anemic groups, low and very low Hb and high Hb
group, were arbitrarily deﬁned. Indeed, while normal and low values
of Hb are well established for men and women, both deﬁnitions of the
cutoff for high Hb (N15 g/dL) and for very low Hb (b11 g/dL) are truly
arbitrary.
Thirdly, patients with severe HF unable to perform CPET, either due
to severe anemia or due to severe HF, were not analyzed. Therefore, our
conclusions should be considered only for HF patients capable to per-
form CPET, regardless of Hb level. Finally, as regards CPET safety, it is
recognized that minor safety issues are difﬁcult to evaluate and, most
importantly, they might have not been recorded. Consequently, only
the occurrence of major (death or cardiac arrest) CPET-related events
was excluded.
Fig. 4.Multivariablemodel forHazard Ratio according toHemoglobin group. Hazard Ratio for association between peak oxygen consumption (VO2), ventilatory efﬁciency (VE/VCO2), Na+,
left ventricle ejection fraction (LVEF), renal function (MDRD), Hb and cardiovascular death+heart transplant through study follow-up in patientswith normal Hb (left upper panel), high
Hb (right upper panel), very low Hb (left lower panel) and low Hb (right lower panel). Each variable is adjusted for the other variables of the model (VO2, VE/VCO2, Na+, LVEF, MDRD).
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Our study shows several relevant ﬁndings: a) anemic HF patients
have a worse prognosis; b) CPET can be safely performed in HF patients
with anemia; c) peakVO2, but not VE/VCO2, is a strong survival predictor
in severe anemia, underlining the importance of performing CPET for
prognosis evaluation in anemicHFpatients; d) peakVO2 and LVEFmain-
tain their validity as prognostic predictors in the anemia setting, sug-
gesting the use of a multiparametric prognostic approach also in HF
patients with low Hb. However, it is unknown whether, during the
prolonged follow-up, anemia status changed and whether anemia cor-
rection was done. Indeed, both spontaneous Hb values changes and
anemia correction could have inﬂuenced the present ﬁndings. Indeed,
an anemia-oriented follow-up of patients is desirable, but it was notstandardized in the present study, and its results are, at present,
unavailable.
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Appendix A
Other MECKI Score Group members are:
– Centro Cardiologico Monzino, IRCCS, Milano: Carlo Vignati, Valentina
Mantegazza, Emanuele Spadafora;
– Cardiologia Riabilitativa, Ospedali Riuniti, Ancona: Francesca Pietrucci;
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– Azienda Ospedaliera Sant'Andrea, “Sapienza” Università degli Studi di
Roma, Roma: Matteo Casenghi.
– Cardiologia SUN, Ospedale Monaldi, Napoli: Teo Roselli, Andrea
Buono, Raffaele Calabrò, Daniele Masarone, Giuseppe Pacileo;
– “S. Maugeri” Foundation, IRCCS, Cassano Murge: Andrea Passantino;
– “S. Maugeri” Foundation, IRCCS, Tradate: Donatella Bertipaglia,
Raffaella Vaninetti;
– Ospedali Riuniti and University of Trieste: Elena Zambon, Marco
Morosin;
– Cardiology, University of Civil Hospital, Brescia: Livio Dei Cas,
Valentina Carubelli;
– UOC Cardiologia, G da Saliceto Hospital, Piacenza: Giovanni Quinto
Villani;
– Fondazione Gabriele Monasterio, CNR-Regione Toscana, Pisa: Luigi
Pastormerlo.
– S. Luca Hospital, Istituto Auxologico Italiano. Milano: Gabriella
Malfatto, Elena Viganò.
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